Myositis (Idiopathic Inflammatory Myopathy, IIM) are auto-immune diseases related to muscles. They are not hereditary. They are characterized by a muscle weakness and fatigability, and very often by muscle pain (myalgia).


Clinical trials ongoing at the Institute:

  • ADSVF-in-IBM: Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial
  • IgPro20_3007: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
  • MASC : Creation of a computerized database of inflammatory myopathies associated with a biobank: MASC project (Myositis, Muscles, DNA/RNA Serum Cells)






Intervention Cell therapy Hizentra
Principal investigator Olivier Benveniste Olivier Benveniste Olivier Benveniste
Sponsor APHP CSL Behring APHP
Pathology IBM DM IIM
Study status In preparation Ongoing Ongoing
Recruitment status In preparation Ongoing Ongoing
Population Adult Adult Adult
+ infos on